恢复期血浆治疗 COVID-19：美国国立卫生研究院 COVID-19 治疗指南专家组的观点。
Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel.
机构信息
National Institutes of Health, Bethesda, Maryland (A.K.P., P.C., H.C.L., H.M., K.S.).
Icahn School of Medicine at Mount Sinai, New York, New York (J.A.).
出版信息
Ann Intern Med. 2021 Jan;174(1):93-95. doi: 10.7326/M20-6448. Epub 2020 Sep 25.
Abstract
In the United States, the efficacy and safety of convalescent plasma for treating coronavirus disease 2019 (COVID-19) is currently being tested in randomized placebo-controlled clinical trials. Treatment of individual patients with COVID-19 with convalescent plasma outside such trials is also now permitted through U.S. Food and Drug Administration Emergency Use Authorization. Here, members of the National Institutes of Health COVID-19 Treatment Guidelines Panel provide their views regarding use of convalescent plasma for treating COVID-19.
摘要
在美国，恢复期血浆治疗 2019 年冠状病毒病（COVID-19）的疗效和安全性目前正在随机安慰剂对照临床试验中进行测试。在美国食品和药物管理局（FDA）紧急使用授权下，现在也允许在这些试验之外，对 COVID-19 患者个体使用恢复期血浆进行治疗。在此，美国国立卫生研究院（NIH）COVID-19 治疗指南专家组的成员提供了他们对使用恢复期血浆治疗 COVID-19 的看法。
相似文献
1
Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel.
Ann Intern Med. 2021 Jan;174(1):93-95. doi: 10.7326/M20-6448. Epub 2020 Sep 25.
2
Convalescent blood plasma (CBP) donated by recovered COVID-19 patients - A comment.
Transfus Apher Sci. 2021 Jun;60(3):103108. doi: 10.1016/j.transci.2021.103108. Epub 2021 Mar 2.
3
Controlled trials needed to prove efficacy and safety of convalescent plasma therapy in coronavirus disease 2019.
Ann Allergy Asthma Immunol. 2021 Feb;126(2):122-123. doi: 10.1016/j.anai.2020.11.005. Epub 2020 Nov 5.
4
Update on and Future Directions for Use of Anti-SARS-CoV-2 Antibodies: National Institutes of Health Summit on Treatment and Prevention of COVID-19.
Ann Intern Med. 2022 Jan;175(1):119-126. doi: 10.7326/M21-3669. Epub 2021 Nov 2.
5
Emergency Approvals for COVID-19: Evolving Impact on Obligations to Patients in Clinical Care and Research.
Ann Intern Med. 2021 Feb;174(2):256-257. doi: 10.7326/M20-6703. Epub 2020 Nov 3.
6
Recommendations on the use of COVID-19 Convalescent Plasma to Treat Immunocompromised Patients.
Semin Thromb Hemost. 2024 Jun;50(4):648-653. doi: 10.1055/s-0043-1776876. Epub 2023 Nov 20.
7
Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
Acta Med Indones. 2021 Jan;53(1):86-95.
8
Convalescent Plasma: Education and Administration Implications.
Clin J Oncol Nurs. 2021 Feb 1;25(1):28-32. doi: 10.1188/21.CJON.28-32.
9
The resurgence of convalescent plasma therapy.
Lancet Haematol. 2020 May;7(5):e353. doi: 10.1016/S2352-3026(20)30117-4.
10
Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency.
J Clin Immunol. 2022 Feb;42(2):253-265. doi: 10.1007/s10875-021-01193-2. Epub 2021 Dec 10.
引用本文的文献
1
Genomic Surveillance of SARS-CoV-2 in Ibadan, Oyo State, Nigeria.
Clin Infect Dis. 2025 Jul 22;80(Supplement_1):S29-S36. doi: 10.1093/cid/ciaf056.
2
A Retrospective Data Audit of Outcome of Moderate and Severe Covid-19 Patients Who Had Received MP and Dex: A Single Center Study.
Infect Drug Resist. 2024 Dec 9;17:5491-5505. doi: 10.2147/IDR.S418788. eCollection 2024.
3
Arterial floating mural thrombi are a characteristic imaging pattern in SARS-CoV-2-related ischemic stroke.
PLoS One. 2024 Oct 25;19(10):e0311622. doi: 10.1371/journal.pone.0311622. eCollection 2024.
4
COVID-19: Recent Insight in Genomic Feature, Pathogenesis, Immunological Biomarkers, Treatment Options and Clinical Updates on SARS-CoV-2.
Curr Genomics. 2024 Apr 8;25(2):69-87. doi: 10.2174/0113892029291098240129113500.
5
Survival implications vs. complications: unraveling the impact of vitamin D adjunctive use in critically ill patients with COVID-19-A multicenter cohort study.
Front Med (Lausanne). 2023 Aug 24;10:1237903. doi: 10.3389/fmed.2023.1237903. eCollection 2023.
6
Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications.
Front Immunol. 2023 Jan 19;14:1055457. doi: 10.3389/fimmu.2023.1055457. eCollection 2023.
7
Accuracy of serological tests for COVID-19: A systematic review and meta-analysis.
Front Public Health. 2022 Dec 16;10:923525. doi: 10.3389/fpubh.2022.923525. eCollection 2022.
8
Ivermectin-Induced Clinical Improvement and Alleviation of Significant Symptoms of COVID-19 Outpatients: A Cross-Sectional Study.
Iran J Sci Technol Trans A Sci. 2022;46(5):1369-1375. doi: 10.1007/s40995-022-01349-8. Epub 2022 Sep 25.
9
A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment.
Biomed Pharmacother. 2022 Sep;153:113499. doi: 10.1016/j.biopha.2022.113499. Epub 2022 Aug 2.
10
Incidence and predictors of death from COVID-19 among patients admitted to treatment center of Wollega University Referral Hospital, Western Ethiopia: A retrospective cohort study.
PLoS One. 2022 Jul 27;17(7):e0267827. doi: 10.1371/journal.pone.0267827. eCollection 2022.
Zotero 插件